scholarly journals Detection and clinical significance of DNA repair gene ERCC8 tag SNPs in gastric cancer

2018 ◽  
Vol 29 (4) ◽  
pp. 392-396 ◽  
Author(s):  
Xingre Lu ◽  
◽  
Fengyu Chen ◽  
Xiaowen Liu ◽  
Diao Yuan ◽  
...  
2011 ◽  
Vol 35 (2) ◽  
pp. 170-174 ◽  
Author(s):  
Tao Yuan ◽  
Shaoli Deng ◽  
Ming Chen ◽  
Wei Chen ◽  
Weiping Lu ◽  
...  

2013 ◽  
Vol 14 (10) ◽  
pp. 6103-6108 ◽  
Author(s):  
Jing-Wei Liu ◽  
Cai-Yun He ◽  
Li-Ping Sun ◽  
Qian Xu ◽  
Cheng-Zhong Xing ◽  
...  

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 12-12
Author(s):  
Jinjia Chang ◽  
Midie Xu ◽  
Hui Sun ◽  
Wenhua Li ◽  
Min Ye ◽  
...  

12 Background: DNA repair genes can be used as prognostic biomarkers in many types of cancer. We aimed to identify prognostic DNA repair genes in patients with gastric cancer (GC) by systematically bioinformatic approaches using web-based database. Methods: Global gene expression profiles from altogether 1,325 GC patients’ samples from six independent datasets were included in the study. Clustering analysis was performed to screen potentially abnormal DNA repair genes related to the prognosis of GC, followed by unsupervised clustering analysis to identify molecular subtypes of GC. Characteristics and prognosis differences were analyzed among these molecular subtypes, and modular key genes in molecular subtypes were identified based on changes in expression correlation. Multivariate Cox proportional hazard analysis was used to find the independent prognostic gene. Kaplan-Meier method and log-rank test was used to estimate correlations of key DNA repair genes with GC patients’overall survival. Results: There were 57 key genes significantly associated to GC patients’ prognosis, and patients were stratified into three molecular clusters based on their expression profiles, in which patients in Cluster 3 showed the best survival (P < 0.05). After a three-phase training, test and validation process, the expression profile of 13 independent key DNA repair genes were identified can classify the prognostic risk of patients. Compared with patients with low-risk score, patients with high risk score in the training set had shorter overall survival (P < 0.0001). Furthermore, we verified equivalent findings by these key DNA repair genes in the test set (P < 0.0001) and the independent validation set (P = 0.0024). Conclusions: Our results suggest a great potential for the use of DNA repair gene profiling as a powerful marker in prognostication and inform treatment decisions for GC patients.


Gene ◽  
2012 ◽  
Vol 511 (2) ◽  
pp. 274-279 ◽  
Author(s):  
Zhipeng Duan ◽  
Caiyun He ◽  
Yantao Gong ◽  
Ping Li ◽  
Qian Xu ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (12) ◽  
pp. e28971 ◽  
Author(s):  
Dongying Gu ◽  
Meilin Wang ◽  
Shizhi Wang ◽  
Zhengdong Zhang ◽  
Jinfei Chen

2004 ◽  
Vol 206 (1) ◽  
pp. 51-58 ◽  
Author(s):  
Hongbing Shen ◽  
Xinru Wang ◽  
Zhibin Hu ◽  
Zhengdong Zhang ◽  
Yaochu Xu ◽  
...  

Author(s):  
Binbin Yuan ◽  
Chengfei Jiang ◽  
Lingyan Chen ◽  
Jinlong Cui ◽  
Min Chen ◽  
...  

Gastric cancer is a heterogeneous group of diseases with only a fraction of patients responds to immunotherapy. The relationships between tumor DNA damage response, the immune system and immunotherapy have recently attracted attention. Accumulating evidence indicate that DNA repair landscape is a significant factor in driving response to immune checkpoint blockade (ICB) therapy. In this study, to explore new prognostic and predictive biomarkers for gastric cancer patients who are sensitive and responsible to immunotherapy, we developed a novel 15-DNA repair gene signature (DRGS) and its related scoring system and evaluated the efficiency of DRGS in discriminating different molecular and immune characteristics and therapeutic outcomes of gastric adenocarcinoma. The results showed that DRGS high score patients showed significantly better therapeutic outcomes compared to DRGS low score patients (P &lt; 0.001). Integrated analysis of multi-omics data demonstrated that the patients with high DRGS score were characteristic of high levels of anti-tumor lymphocytes infiltration, tumor mutation burden (TMB) and PD-L1 expression, and these patients exhibited a longer overall survival and may benefit more from ICB therapy, as compared to the low-score patients. Therefore, the DRGS and its scoring system may have implications in tailoring immunotherapy in gastric cancers.


Tumor Biology ◽  
2014 ◽  
Vol 35 (8) ◽  
pp. 7569-7574 ◽  
Author(s):  
Junkai Li ◽  
Xiaoyan Zuo ◽  
Xiaoyan Lv ◽  
Fanjun Kong ◽  
Wen Xu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document